Nail and hair findings developing in patients treated for COVID-19 infection fluorescence of keratinized tissues on Wood’s lamp in COVID-19 disease

Abstract

Background: The new severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is the causative agent of coronavirus 2019 (COVID-2019) disease. A wide variety of symptoms of the disease has been frequently reported in the literature in recent years. However, information on the findings in keratinized tissues is still limited. Data on changes in keratinized tissues such as nails, teeth and hair, and oral mucousa due to drugs used in the treatment of this disease are also extremely insufficient. Aim: With this study, it was aimed to evaluate the changes in the keratinized tissues of our patients with COVID-19, who are frequently encountered in the Ear Nose and Throat outpatient clinic. Materials and Method: The study was carried out on patients who applied to Başkent University Ear Nose and Throat clinic. There were 3 groups. The first group consisted of patients diagnosed with COVID-19 and received relevant medical treatments, the second group included individuals who have never experienced COVID-19 infection but have been vaccinated against COVID-19, and the third group is the control group with normal healthy individuals who have never been diagnosed with COVID-19 infection and have not been vaccinated so far. With the Wood's lamp, fluorescent changes in nails, hair, tooth, and the oral mucousa were recorded. Results: A total of 124(75 females, 49 males) patients were included in the study. Positive Wood's finding was significantly higher in COVID-19 group(Group 1) who received Favipravir when compared with individuals who did not receive Favipravir (p < 0.001). Wood's positivity was not detected in any of the individuals who did not use favipravir. The rate of determining Wood's positivity in favipravir users decreases after 58 days. Discussion: Accordingly, Favipravir accumulation in the kretainized tissues manifest positive Wood's sign in our study. Conclusion: The adverse effects of the accumulation of the drugs—mainly Favipravir—used in the treatment of COVID-19 disease, have not yet been clearly demonstrated so far. Revealing the findings in these tissues with this study will pave the way for investigating changes or drug sequestrations in other organs in the long term.